Title of Invention

A PROCESS FOR THE PREPARATION OF HEPARIN BONDED POLYOLEFIN

Abstract THE PROCESS FOR THE PREPARATION OF HEPARIN BONDED POLYOLEFIN THE STEPS OF CLEANING THE POLYOLEFIN IN AN ORGANIC SHEET POLYPROPYLENE.
Full Text FIELD OF THE INVENTION
This invention relates to a process for the preparation of heparin bonded olefin polymers
and the olefin polymers prepared thereby.
BACKGROUND OF THE INVENTION
Heparin is a naturaity occurring mucopolysaccharide composed of repeating units of
disaccharides. The principal anticoagulant effect of heparin is due to its ability to
accelerate the inhibition of thrombin factor Xa by AT HL The effect of heparin on fibrin
clot formation extends beyond its direct effect of neutralisation of thrombin and Xa In the
absence of heparin or other anticoagulants fibrinogen rapidly coats foreign surfaces and
platelets adhere to fibrinogen soon thereafter. Systemic administration of heparin even in
enormous doses used for CPB, incompletely prevents adherence of fibrinogen and platelets
to synthetic surfaces. Blood coagulation remains active during CPB despite profound
anticoagulation with heparin. Protamine activates complement, causes vasodilation and can
cause life-threatening anaphylaxis or pulmonary hyper tension
In order to reduce the drawbacks of heparinization of blood, attempts were made for the
immobilization of heparin on to devices for blood contacting applications.
Cardiopulmonary applications like membrane oxygenator, catheters, etc. are a few to
mention among them The effect of protein adsorption of the anticoagulant activity of
surface immobilised heparin on to carboxyiated polystyrene beads was determined by
Vandelden et al (X Biomater. Sci. Polym. Ed 7,8; 727-740, 1996) and was found
promising.
Different methods of immobilisation of heparin had been attempted. Heparin being a
complex macro molecular organic polysaccharides with high negative charges can bind to
positively charged matrices. Such ionic binding has been materialised by Eberle, Manton
& Meals (J. Biomed Mater. Res.7:145-153,1973), with quaternary ammonium compounds
which in turn is bound to synthetic surfaces like polyethylene and poly vinyl chloride. But
stability of such ionically linked heparin is poor when compared to covalently bound
heparin. Other methods of coating include that with the carbodiimide method
Polyvinyl Chloride Heparin has earlier been bound or immobilised with (pVA)to a hydrogel. Other matrices
which had been tried to be coated with heparin include ^MMA.) Ajrart from mis, biological
substrates like collagen have been immobilised with heparin
Poly propylene had been coated with heparin by the Duraflo II (Universal coating) and the
platelet adhesion of the coated sample has been studied It has been found that they have
better blood compatibility, lesser blood material interaction and micro embolisation
prevention capabilities. For universal coating, the physio chemical properties of the

unfractionated heparin are modified with a proprietary binding agent The resulting
material Duraflo II heparin has high affinity to a variety of synthetic surfaces. They retain
all anti-coagulation properties of heparin.
Different synthetic materials have been used for the fabrication of devices like
Polyvinyl Chloridi polycarbonate (for oxygenator shell), polypropylene (for membrane oxygenator) blood bags), polyethylene (for catheters) and so on.
OBJECTS OF THE INVENTION
It is therefore an object of this invention to propose heparin bonded polyolefin which does
not affect the mechanical properties of me polyolefin.
It is a further object of mis invention to propose heparin bonded polyolefin which retains
the surface profile of the polymer after modification.
Another object of mis invention is to propose heparin bonded potyolefin which is stable.
DESCRIPTION OF THE INVENTION
Thus according to this invention is provided a process for the preparation of heparin
bonded polyolefin comprising the steps of cleaning the polyolefin in an organic solvent and
drying, followed by treatment with an oxidizing agent such as an inorganic salt alone or in
combination with an acid, and washing the treated sample, introducing the washed treated
sample into a diimide solution followed by washing, treatment with a heparin solution,
further washing and drying to obtain the heparin bonded polyolefin.
According to mis invention is further provided heparin bonded olefin polymers.
In accordance with this invention, Polyethylene (PE) sheets of commercial grade or high
quality or polypropylene sheets or hollow fibres are cleaned with an organic solvent like
Chloroform (CHCI3) Dimethyl acetamide (DMAc), dichloromethane (CH2CI2) or dimethyl
sulphoxide (DMSO) or inorganic reagents like hydrogen peroxide nitric acid. The cleaned
polymer is dried at 50-130°C for a period of one hour. They are then treated with an
oxidising agent of inorganic origin. The inorganic salts that may be used for the purpose are
Sodium Nitrate, Sodium Chromate, Potassium permanganate, Sodium peroxide either alone
or in combination with other acids such as Nitric acid, Hydrochloric acid or Sulphuric
acid of suitable strength.
Polyethylene sheets of lxl cm size are cut from large sheets or polypropylene hollow
fibres of about 275 microns are cut into strips of about 1 cm in length with a fine scalpel.
They are washed with water, dried and introduced into a solution containing about 50-
100% nitric acid, hydrochloric acid or sulphuric acid alone or in combination with about
1-10% by weight of sodium nitrate or potassium dichromate, potassium permanganate, etc..
The treated samples are washed in distilled water. They are introduced into a 5-250 mg%



0.0005gm of the dye was dissolved in .001% wt/wt of HCl containing .002% by wt Of
NaCI. 0.0.243gm of the modified hollow fibre sample was put into 5ml of the dye solution.
After 30 mins., the samples were taken out A control was done using unmodified
polypropylene hollow fibers.
On visual examination, a violet colouration was observed on the modified samples which
was absent in the unmodified samples. This was due to the attachment of the dye molecules
on to the heparin molecules. The absorbance of the remaining dye solution was monitored
using a double beam Shimadsu Spectrophotometer at 63 Iran wave length. From a standard
curve prepared from known amounts of the dye, the absorbance of the remaining solution
from each sample was found out
Absorbance of the following samples were measured
1. Reagent blank- "B* (The dye solution used for the dye depletion study)
2. Three control samples "01,02,03" (unmodified control samples of almost equal
weight)
3. Three modified samples "M1,M2,M3" (heparin bonded samples of almost equal
weight)

Load at break
The load at break of the modified polypropylene was compared with that of the unmodified sample in a tensile strength testing machine.
A single strand of the hollow fibre was cut to a length of about 5cm. It was gripped to the jaws of the testing machine (Instron, Model 1011). The grip speed was set to 200 mm/mia lit was found that the average load at break was 1.71875.Newtons for the unmodified and 1.70S8 Newtons for the modified samples. It was found that there was no remarkable change in the mechanical properties either.


Hence, it can be understood that the surface properties and mechanical properties are not affected by the modification.


WE CLAIM:
1. A process for the preparation of heparin bonded polyolefin comprising the steps of cleaning the polyolefln in an organic solvent and drying, followed by treatment with an oxidizing agent such as an inorganic salt alone or in combination with an acid, and washing the treated sample, introducing the washed treated sample into a diimide solution followed by washing, treatment with a heparin solution, further washing and drying to obtain the heparin bonded polyolefin.
2. The process as claimed in claim 1 wherein said polyolefln is a polymer such as polyethylene, polypropylene.
3. The process as claimed in claim 1 wherein the polyolefin sample is in the form of sheets or hollow fibres.
4. The process as claimed in claim 1 wherein the organic solvent used for cleaning the polyolefin sample is selected from chloroform (CHCfe), dimethyl sulphoxide (DMSO)
5. The process as claimed in claim 1 wherein the polyolefin is optionally cleaned with hydrogen peroxide or nitric acid.
6. The process as claimed in claim 1 wherein the cleaned polyolefin is dried at 50-130°C. ,
7. The process as claimed in claim I wherein said oxidising agent is an inorganic salt such as sodium nitrate, sodium chromate, potassium permanganate, sodium peroxide, sodium dichromate, potassium dicbromate, ammonium persulphate.
8. The process as claimed in claim 1 wherein the acid used is a mineral acid such as nitric acid, hydrochloric acid, sulphuric acid.
9. The process as claimed in claim 1 wherein for die treatment wim the oxidising agent, a 50-100% mineral acid is used with 1 to 10% by weight of the inorganic salt
10. The process as claimed in claim 1 wherein the polyolefin samples, after treatment with the oxidising agent, are washed with distilled water.
11. The process as claimed in claim 1 wherein the diimide compound is l-propyl-3-(3-dipropyl aminopropyl) carbodiimide, 2-ethyl-3-(3-diethyI aminoethyl) carbodiimide, l-ethyl-3-(3-dimediyl aminopropyl) carbodiimide etc. having different carbonyl groups attached to the different nitrogen atoms.
12. The process as claimed in claim 1 wherein the treatment with diimide solution is carried out at apH of 3.5-8.5 of a suitable buffer.
13. The process as claimed in claim 1 wherein the treatment with the diimide solution is carried out over a period in the range of 1 and 15 hrs..

14. The process as claimed in claim 1 wherein the treatment with the diimide solution is
carried out at a temperature in the range of 15 and 5 06C.
15. The process as claimed in claim 1 wherein for the treatment with diimide solution, a 5
to 250 mg% solution is used.
16. The process as claimed in claim 1 wherein the diimide treated polyolefin samples are
washed with distilled water.
17. The process as claimed in claim 1 wherein treatment with the heparin solution is
carried out at a pH of 3 to 8.5.
18. The process as claimed in claim 1 wherein a solution of heparin is used. ~^
19. The process as claimed in claim 1 wherein the heparin treated samples after washing,
are dried at 30 to 40°C.
20. Heparin bonded polyolefin. >
21. A process for the preparation of heparin bonded polyolefin substantially as herein described and illustrated
22. Heparin bonded polyolefin substantially as herein described and illustrated.
Dated this 5th day of NOVEMBER, 2002.

Documents:

0825-mas-2002 claims duplicate.pdf

0825-mas-2002 claims.pdf

0825-mas-2002 description (complete) duplicate.pdf

0825-mas-2002 description (complete).pdf

0825-mas-2002 drawings.pdf

825-mas-2002- correspondence others.pdf

825-mas-2002- correspondence po.pdf

825-mas-2002- form 1.pdf

825-mas-2002- form 19.pdf

825-mas-2002- form 26.pdf

825-mas-2002- form 3.pdf


Patent Number 207533
Indian Patent Application Number 825/MAS/2002
PG Journal Number 44/2007
Publication Date 02-Nov-2007
Grant Date 14-Jun-2007
Date of Filing 11-Nov-2002
Name of Patentee SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES & TECHNOLOGY
Applicant Address SATELMOND PALACE,TRIVANDRUM 695 012.
Inventors:
# Inventor's Name Inventor's Address
1 LEISTER ROWSEN MOSES SATELMOND PALACE,TRIVANDRUM 695 012.
PCT International Classification Number A61K31/725
PCT International Application Number N/A
PCT International Filing date
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 NA